Last reviewed · How we verify
Dihydroxycholecalciferols
Dihydroxycholecalciferols is a Small molecule drug developed by Tishreen University. It is currently in Phase 2 development.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Dihydroxycholecalciferols |
|---|---|
| Sponsor | Tishreen University |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Effect of Local Use of Vitamin D on the Rate of Canine Distillization: a Split Mouth Randomized Control Trial (PHASE1)
- Effects of Vitamin D in Patients Undergoing Fixed Orthodontic Mechanotherapy (NA)
- Genetics of Response to Canagliflozin (PHASE1)
- Vitamin D in OUD: Exploration of Alterations on the Dopamine D2/D3 Receptor System (PHASE1)
- Calcitriol Monotherapy for X-Linked Hypophosphatemia (EARLY_PHASE1)
- Activated Vitamin D for the Prevention and Treatment of Acute Kidney Injury (PHASE2)
- Safety and Efficacy of Hectorol in Pediatric Patients With Chronic Kidney Disease Stage 3 and 4 With Secondary Hyperparathyroidism Not Yet on Dialysis (PHASE3)
- DePTH: De-emphasize PTH (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Dihydroxycholecalciferols CI brief — competitive landscape report
- Dihydroxycholecalciferols updates RSS · CI watch RSS
- Tishreen University portfolio CI
Frequently asked questions about Dihydroxycholecalciferols
What is Dihydroxycholecalciferols?
Who makes Dihydroxycholecalciferols?
What development phase is Dihydroxycholecalciferols in?
Related
- Manufacturer: Tishreen University — full pipeline
- Therapeutic area: All drugs in Other
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing